[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Kong et al., 2023 - Google Patents

Multifunctional Probe Based on “Chemical Antibody–Aptamer” for Noninvasive Detection of PD-L1 Expression in Cancer

Kong et al., 2023

Document ID
11668034986833667285
Author
Kong S
Liu Q
Chen Y
Liang B
Zhou Y
Lin J
Xie M
Qiu L
Publication year
Publication venue
Molecular Pharmaceutics

External Links

Snippet

Immune checkpoint inhibitors (ICIs) therapy based on programmed cell death ligand 1 (PD- L1) has shown significant development in treating several carcinomas, but not all patients respond to this therapy due to the heterogeneity of PD-L1 expression. The sensitive and …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Mahalingam et al. Evaluation of novel tumor-targeted near-infrared probe for fluorescence-guided surgery of cancer
Wang et al. Development of targeted near-infrared imaging agents for prostate cancer
JP7455510B2 (en) Compositions and methods for targeted particle penetration, distribution and response in malignant brain tumors
Wang et al. NIR scaffold bearing three handles for biocompatible sequential click installation of multiple functional arms
He et al. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor
Liu et al. 99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma
Chen et al. Melanocortin-1 receptor-targeting ultrasmall silica nanoparticles for dual-modality human melanoma imaging
Hensbergen et al. Image-guided surgery: are we getting the most out of small-molecule prostate-specific-membrane-antigen-targeted tracers?
Wang et al. Radioligand therapy of prostate cancer with a long-lasting prostate-specific membrane antigen targeting agent 90Y-DOTA-EB-MCG
Lv et al. Prostate-specific membrane antigen targeted therapy of prostate cancer using a DUPA–paclitaxel conjugate
Machulkin et al. Synthesis and biological evaluation of PSMA ligands with aromatic residues and fluorescent conjugates based on them
Lu et al. A dual reporter iodinated labeling reagent for cancer positron emission tomography imaging and fluorescence-guided surgery
Kanduluru et al. Design, synthesis, and evaluation of a neurokinin-1 receptor-targeted near-IR dye for fluorescence-guided surgery of neuroendocrine cancers
Huang et al. Development of 5D3-DM1: A novel anti-prostate-specific membrane antigen antibody-drug conjugate for PSMA-positive prostate cancer therapy
Zhou et al. A novel near-infrared fluorescent probe TMTP1-PEG4-ICG for in vivo tumor imaging
Ke et al. Targeting the tumor-associated folate receptor with an 111In− DTPA conjugate of pteroic acid
Zhang et al. PET imaging of VCAM-1 expression and monitoring therapy response in tumor with a 68Ga-labeled single chain variable fragment
Reeßing et al. A facile and reproducible synthesis of near-infrared fluorescent conjugates with small targeting molecules for microbial infection imaging
Meher et al. Prostate-specific membrane antigen targeted deep tumor penetration of polymer nanocarriers
Wang et al. Molecular imaging of P-glycoprotein in chemoresistant tumors using a dual-modality PET/fluorescence probe
Cilibrizzi et al. PSMA-targeted NIR probes for image-guided detection of prostate cancer
Li et al. De novo computational design for development of a peptide ligand oriented to VEGFR-3 with high affinity and long circulation
Hernandez Vargas et al. High-contrast detection of somatostatin receptor subtype-2 for fluorescence-guided surgery
Cheng et al. Targeting to overexpressed glucose‐regulated protein 78 in gastric cancer discovered by 2D DIGE improves the diagnostic and therapeutic efficacy of micelles‐mediated system
Kim et al. In Vivo Imaging of Mesenchymal− Epithelial Transition Factor (c-Met) Expression using an Optical Imaging System